Ruth A Karron

Summary

Affiliation: Johns Hopkins Bloomberg School of Public Health
Country: USA

Publications

  1. ncbi Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant
    R A Karron
    Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD 21205, USA
    Proc Natl Acad Sci U S A 94:13961-6. 1997
  2. ncbi Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children
    Ruth A Karron
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Vaccine 30:3975-81. 2012
  3. ncbi A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults
    Ruth A Karron
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
    J Infect Dis 199:711-6. 2009
  4. ncbi Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults
    Ruth A Karron
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States
    Vaccine 27:4953-60. 2009
  5. ncbi The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children
    Ruth A Karron
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Pediatr Infect Dis J 30:e186-91. 2011
  6. ncbi Severe respiratory syncytial virus disease in Alaska native children. RSV Alaska Study Group
    R A Karron
    Center for Immunization Research, Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD 21205, USA
    J Infect Dis 180:41-9. 1999
  7. ncbi Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants
    Ruth A Karron
    Center for Immunization Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
    J Infect Dis 191:1093-104. 2005
  8. ncbi An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults
    Kawsar R Talaat
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States
    Vaccine 29:3144-8. 2011
  9. ncbi A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults
    Kawsar R Talaat
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States
    Vaccine 27:3744-53. 2009
  10. ncbi Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus
    Joshua J Shinoff
    Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
    J Infect Dis 198:1007-15. 2008

Detail Information

Publications26

  1. ncbi Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant
    R A Karron
    Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD 21205, USA
    Proc Natl Acad Sci U S A 94:13961-6. 1997
    ..The requirement of SH and G for efficient replication in vivo suggests that selective deletion of one or both of these RSV genes may provide an alternative or additive strategy for developing an optimally attenuated vaccine candidate...
  2. ncbi Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children
    Ruth A Karron
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Vaccine 30:3975-81. 2012
    ..Taken together, these data suggest that the rB/HPIV3 vaccine is the preferred candidate for further clinical development...
  3. ncbi A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults
    Ruth A Karron
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
    J Infect Dis 199:711-6. 2009
    ..Although replication of the H9N2 LAIV was restricted, 2 doses were immunogenic in H9N2-seronegative adults. Trial registration. ClinicalTrials.gov identifier: NCT00110279 ...
  4. ncbi Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults
    Ruth A Karron
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States
    Vaccine 27:4953-60. 2009
    ..Development of live attenuated influenza vaccines (LAIV) against avian viruses with pandemic potential is an important public health strategy...
  5. ncbi The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children
    Ruth A Karron
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Pediatr Infect Dis J 30:e186-91. 2011
    ..Human parainfluenza virus type 3 (HPIV3) is an important yet underappreciated cause of lower respiratory tract illness in children, and a licensed vaccine is not yet available...
  6. ncbi Severe respiratory syncytial virus disease in Alaska native children. RSV Alaska Study Group
    R A Karron
    Center for Immunization Research, Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD 21205, USA
    J Infect Dis 180:41-9. 1999
    ..2, P=.03). In the YK Delta and at JHH, newborns may be at greater risk for severe RSV illness than previously thought...
  7. ncbi Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants
    Ruth A Karron
    Center for Immunization Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
    J Infect Dis 191:1093-104. 2005
    ..Recombination technology can be used to create live attenuated respiratory syncytial virus (RSV) vaccines that contain combinations of known attenuating mutations...
  8. ncbi An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults
    Kawsar R Talaat
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States
    Vaccine 29:3144-8. 2011
    ..We describe the results of an open label Phase I trial of a live attenuated H6N1 influenza virus vaccine (ClinicalTrials.gov Identifier: NCT00734175)...
  9. ncbi A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults
    Kawsar R Talaat
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States
    Vaccine 27:3744-53. 2009
    ..Live attenuated influenza vaccines (LAIVs) are being developed and tested against a variety of influenza viruses with pandemic potential. We describe the results of an open-label Phase I trial of a live attenuated H7N3 virus vaccine...
  10. ncbi Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus
    Joshua J Shinoff
    Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
    J Infect Dis 198:1007-15. 2008
    ..RSV can induce substantial neutralizing antibody responses in young infants when the titer of preexisting antibodies is low...
  11. ncbi Use and evaluation of molecular diagnostics for pneumonia etiology studies
    Niranjan Bhat
    Department of International Health, Johns Hopkins Bloomberg School of Public Health
    Clin Infect Dis 54:S153-8. 2012
    ....
  12. ncbi An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults
    Kawsar R Talaat
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Influenza Other Respi Viruses 7:66-73. 2013
    ..Live attenuated influenza vaccines (LAIV) against a variety of strains of pandemic potential are being developed and tested. We describe the results of an open-label phase I trial of a live attenuated H2N2 virus vaccine...
  13. ncbi rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    J Infect Dis 191:710-8. 2005
    ..The live attenuated dengue virus type 4 (DEN-4) vaccine candidate virus rDEN4 Delta 30 was previously found to be safe and immunogenic at a dose of 10(5) plaque-forming units (pfu)...
  14. ncbi A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults
    Kawsar R Talaat
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    J Infect Dis 202:1327-37. 2010
    ..When the novel H1N1 influenza A strain appeared in April of 2009, development of novel H1N1 vaccines became a public health priority...
  15. ncbi The future of respiratory syncytial virus vaccine development
    Fernando P Polack
    Department of Intenational Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
    Pediatr Infect Dis J 23:S65-73. 2004
    ..CONCLUSIONS: During the past 10 years, considerable progress has been made in RSV vaccine development. It is likely that different RSV vaccines will be needed for the various populations at risk...
  16. ncbi A role for immune complexes in enhanced respiratory syncytial virus disease
    Fernando P Polack
    Department of Pediatrics, School of Medicine, Bloomberg School of Public Health at Johns Hopkins University, Baltimore, MD 21205, USA
    J Exp Med 196:859-65. 2002
    ..Further, we show correlation with the enhanced disease observed in children by providing evidence of complement activation in postmortem lung sections from children with enhanced RSV disease...
  17. ncbi The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin
    Fernando P Polack
    Department of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Proc Natl Acad Sci U S A 102:8996-9001. 2005
    ..These findings have important implications for RSV pathogenesis and describe an inhibitor of TLR-mediated inflammatory responses that could have clinical applications...
  18. ncbi Specimen collection for the diagnosis of pediatric pneumonia
    Laura L Hammitt
    International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    Clin Infect Dis 54:S132-9. 2012
    ..We discuss the advantages and limitations of each specimen, and discuss the rationale for the specimens to be collected for the Pneumonia Etiology Research for Child Health study...
  19. ncbi Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    Clin Infect Dis 37:1668-77. 2003
    ..Recombinant technology allows candidate vaccines to be "fine-tuned" in response to clinical data, which should hasten the development of vaccines against these important respiratory pathogens...
  20. ncbi Respiratory syncytial virus infection in Navajo and White Mountain Apache children
    Jana Bockova
    Johns Hopkins University School of Medicine, Division of Pediatric Infectious Diseases, Baltimore, Maryland, USA
    Pediatrics 110:e20. 2002
    ..A lower threshold for hospitalization or underlying chronic conditions that predispose to severe RSV disease do not seem to explain high RSV hospitalization rates in this population...
  21. ncbi Attenuation of live respiratory syncytial virus vaccines is associated with reductions in levels of nasal cytokines
    Ruth A Karron
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health
    J Infect Dis 207:1773-9. 2013
    ..Levels of cytokines in NW specimens may be useful biomarkers of attenuation for live RSV vaccines...
  22. ncbi Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region
    A P Durbin
    Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland 21205, USA
    Am J Trop Med Hyg 65:405-13. 2001
    ..The low level of reactogenicity and high degree of immunogenicity of this vaccine candidate warrant its further evaluation and its use to create chimeric vaccine viruses expressing the structural genes of dengue virus types 1, 2, and 3...
  23. ncbi Disk diffusion bioassays for the detection of antibiotic activity in body fluids: applications for the Pneumonia Etiology Research for Child Health project
    Amanda J Driscoll
    International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, 855 N Wolfe St, Suite 600, Baltimore, MD 21205, USA
    Clin Infect Dis 54:S159-64. 2012
    ..Although there are limitations to the disk diffusion method, its low cost, ease of use, and ability to broadly detect antibiotic pretreatment make it an appealing method for epidemiologic studies such as PERCH...
  24. ncbi Comparison of temple temperatures with rectal temperatures in children under two years of age
    George K Siberry
    Department of Pediatrics, School of Medicine, The Johns Hopkins University, Baltimore, MD, USA
    Clin Pediatr (Phila) 41:405-14. 2002
    ..The findings do not support use of temple temperatures to screen young infants for rectal fever > or =38.0 degrees C. Temperatures obtained by parents were comparable to those obtained by nurses...
  25. ncbi Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
    C D Harro
    Center for Immunization Research, Department of International Medicine, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD, USA
    J Natl Cancer Inst 93:284-92. 2001
    ....
  26. ncbi A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes
    J M Troyer
    Department of Entomology, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, USA
    Am J Trop Med Hyg 65:414-9. 2001
    ..Most significantly, 2Adelta30 was not transmitted to 352 Ae. albopictus mosquitoes fed on 10 vaccinees, all of whom were infected with the vaccine candidate...